Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Bioventus Expects 2025 Sales Of $560M-$570M Versus Consensus Of $554.62M, With Adjusted EPS Of $0.64 to $0.68 Versus Consensus Of $0.55

Author: Benzinga Newsdesk | March 11, 2025 06:38am

Bioventus introduced its financial guidance for full-year 2025. The Company expects:

Net sales of $560 million to $570 million. This reflects organic growth of approximately 6.1% to 8.0% when including the impact of the Company's divestiture of its Advanced Rehabilitation Business, which generated revenue of $45.4 million in 2024.
Adjusted EBITDA of $112 million to $116 million, reflecting 100 basis points in Adjusted EBITDA Margin growth compared to the 2024 Adjusted EBITDA* Margin of 19.0% when using the low end of the 2025 revenue and Adjusted EBITDA guidance.
Non-GAAP EPS of $0.64 to $0.68, reflecting an increase of 30.6% to 38.8%.

Posted In: BVS